Previous 10 | Next 10 |
Shares of BioXcel Therapeutics (BTAI -21.5%) are down significantly today after Goldman Sachs downgraded the stock to sell from buy. Analyst Corinne Jenkins lowered her price target to $24 from $55 (~30% downside). She notes that the company's consensus estimates don't take into account ...
NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, P...
BioXcel Therapeutics, Inc. (BTAI) Q3 2021 Earnings Conference Call November 10, 2021 08:30 ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Vincent O’Neill - Chief Medical Officer Frank Yocca - Chief Scientific Officer Rob Rising...
BioXcel Therapeutics (NASDAQ:BTAI): Q3 GAAP EPS of -$0.96 beats by $0.11. As of September 30, 2021, cash and cash equivalents totaled approximately $252.9M. Press Release For further details see: BioXcel Therapeutics EPS beats by $0.11
Plans for commercial and launch readiness advancing for BXCL501 orally dissolving film, for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, ahead of January 5, 2022 PDUFA date On track to initiate Phase 3 program for acute...
ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...
NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will releas...
Chasing short-term gains is usually not the best strategy in the stock market. Investing in solid companies and holding their shares for a long time is still the best way to grow your capital. However, some companies with a promising future can provide explosive short-term gains too. Le...
Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrine Prostate Cancer (SCNC) High unmet medical need with no FDA approved thera...
Gainers: Grove (NASDAQ:GRVI) +62%. NRx Pharmaceuticals (NASDAQ:NRXP) +35%. Connect Biopharma (NASDAQ:CNTB) +23%. Huttig Building Products (NASDAQ:HBP) +20%. KORE (NYSE:KORE) +20%. DarioHealth (NASDAQ:DRIO) +19%. Broadwind (NASDAQ:BWEN) +19%. Cemtrex (NASDAQ:CETX) +17%. Annovis (NYSE:ANVS) +17...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...